Market Overview

UPDATE Citi Lowers Price Target on Incyte to $15


According to Citi, Incyte (NASDAQ: INCY) price target is lowered to $15.

Citi said that it conducted a 25-physician survey in Nov. 2011 on the potential clinical adoption of Jakafi (ruxolitinib) in anticipation of the FDA approval. “On average, physicians expect to prescribe Jakafi in ~35% of their overall MF patients.”

Incyte closed on Friday at $14.24.

Posted-In: CitiAnalyst Color Price Target Analyst Ratings


Related Articles (INCY)

View Comments and Join the Discussion!